Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients
NCT05844046
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
83
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL:
durvalumab, tremelimumab, bevacizumab
Sponsor
Enrico De Toni